MolDX: Pigmented Lesion Assay

The Pigmented Lesion Assay (PLA) is covered as a pre-biopsy decision tool for primary melanocytic skin lesions (5–19 mm) with one or more ABCDE features when a clinician trained in skin cancer evaluation is considering biopsy. Coverage is limited to intact, non-scarred, non-ulcerated lesions not located in palms/soles/nails/mucous membranes or areas of psoriasis/eczema, requires documentation (lesion photograph, site, clinician credentials, and monitoring plan), and generally allows one test per lesion and typically one test per clinical encounter (rare exceptions require appeal).

"PLA is indicated for evaluation of primary melanocytic skin lesions when a clinician trained in diagnosing skin cancer is considering whether to perform a biopsy to rule out melanoma."

Sign up to see full coverage criteria, indications, and limitations.